The First Pill for PCSK9: What Enlicitide's Approval Means for Your Lipid Clinic
The FDA has approved enlicitide (Lipfendra) as the first oral PCSK9 inhibitor for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).
It is manufactured by MerckNYSE: MRK, and is dosed as a once-daily 20-mg tablet.
Every prior PCSK9 inhibitor on the US market has required an injection, so this approval changes the practical calculus for a large share of statin-intolerant and high-risk patients.
Enlicitide is a novel macrocyclic peptide that binds PCSK9 and blocks its interaction with hepatic LDL receptors, the same target as the injectable antibodies but delivered as an orally stable ring-shaped peptide.
A 54-year-old patient with heterozygous familial hypercholesterolemia has an LDL-C of 168 mg/dL despite maximally tolerated rosuvastatin and ezetimibe.
The patient has declined every injectable option offered over the past two years, citing needle aversion and a demanding travel schedule that makes cold-chain storage impractical.
An oral, room-temperature-stable PCSK9 inhibitor removes both objections in a single conversation.
This is precisely the patient population most likely to benefit from enlicitide's approval.
What the CORALreef Trials Showed
The approval rests on two Phase 3 trials, CORALreef Lipids and CORALreef HeFH.
In CORALreef Lipids, LDL-C fell 57.1% with enlicitide versus a 3.0% rise with placebo at 24 weeks, an adjusted between-group difference of 55.8%.
In CORALreef HeFH, the between-group LDL-C difference was 59.4%, with both results reaching high statistical significance.
Diarrhea and dizziness were numerically more frequent with enlicitide in the HeFH trial, but discontinuation rates for adverse events were similar between arms.
| Trial | Population | LDL-C Change (Enlicitide vs Placebo) | Notable Adverse Events |
|---|---|---|---|
| CORALreef Lipids | Adults with hypercholesterolemia | -57.1% vs +3.0% (Δ 55.8%, P<0.001) | Similar to placebo overall |
| CORALreef HeFH | Adults with heterozygous FH | Δ 59.4% (P<0.001) | Diarrhea 7% vs 2%; dizziness 9% vs 4% |
Where It Fits Among PCSK9 Inhibitors
Enlicitide joins a crowded but still-growing PCSK9 class that includes inclisiran (Leqvio), evolocumab (Repatha), alirocumab (Praluent), and lerodalcibep (Lerochol).
What sets it apart is not efficacy but the route: a tablet rather than a subcutaneous injection or in-office infusion.
An interventional cardiologist commenting to TCTMD framed this as an access issue rather than a potency issue, since needle aversion and cold-chain logistics keep some appropriate patients from ever starting a PCSK9 inhibitor.
That same commentary was clear that oral PCSK9 inhibition adds to the toolbox rather than replacing existing agents.
Financial Snapshot: The PCSK9 Competitive Landscape
Cost has historically limited broader PCSK9 uptake, and the TCTMD commentary noted that access will hinge on pricing and payer pathways once enlicitide launches commercially.
List pricing for enlicitide has not yet been published as of this approval, so clinicians should expect formulary and coupon details to follow in the coming weeks.
| Agent (Brand) | Company / Ticker | Analyst Consensus & 12-Mo Target | Cash/List Price Reference |
|---|---|---|---|
| Enlicitide (Lipfendra) | MerckNYSE: MRK | Buy · $132.78 target | Not yet published |
| Evolocumab (Repatha) | AmgenNASDAQ: AMGN | Hold · $345.12 target | GoodRx cash price from ~$239/mo |
| Alirocumab (Praluent) | RegeneronNASDAQ: REGN / SanofiNASDAQ: SNY | Buy · $833.31 target (REGN) | GoodRx cash price ~$233/mo |
| Inclisiran (Leqvio) | NovartisNYSE: NVS | Hold · $154.57 target | GoodRx coupon programs vary; list WAC ~$3,250-3,500/dose |
| Lerodalcibep (Lerochol) | LIB Therapeutics no ticker (private) | Not applicable | Cash-pay launch price $199/month |
What's Still Unknown
No cardiovascular outcomes data yet exist for enlicitide, so a reduction in heart attacks and strokes remains inferred rather than proven.
The ongoing CORALreef Outcomes trial has completed enrollment of more than 14,500 participants and should eventually answer that question.
Merck also has an extension study, a pediatric trial in patients ages 6 to 17, and a combination trial pairing enlicitide with rosuvastatin underway.
Until outcomes data mature, enlicitide should be regarded as a highly effective LDL-lowering option with a favorable surrogate-endpoint profile, not yet a confirmed event-reducing therapy.
Enlicitide is the first oral PCSK9 inhibitor, matching injectable-class LDL-C reductions of roughly 56-59% in two Phase 3 trials.
It expands options for patients who decline or cannot manage injectable therapy, without replacing existing agents.
Cardiovascular outcomes data are still pending from the ongoing CORALreef Outcomes trial.
Pricing, insurance coverage, and formulary placement will determine how quickly it reaches appropriate patients.
Related Viewing
For a patient-friendly primer on how this drug class works, see PCSK9 Inhibitors Explained, which covers the mechanism and cardiovascular rationale behind PCSK9 inhibition.
For a clinician-oriented walkthrough of when to use this class in practice, see PCSK9 Inhibitors in Practice.
References
- Merck news release on LIPFENDRA (enlicitide) FDA approval
- AJMC coverage of the enlicitide approval
- TCTMD coverage of the CORALreef Lipids trial
- GoodRx pricing reference for evolocumab (Repatha)
- GoodRx pricing reference for inclisiran (Leqvio)
- LIB Therapeutics LEROCHOL US launch announcement
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.